Profile: VIVUS Inc. is a drug-development company dedicated to the development & commercialization of next-generation therapeutic products addressing obesity and sexual health. Our pipeline includes products in late-stage clinical development addressing obesity and sexual health. We currently have four mid-to-late-stage clinical development programs in progress that target obesity, diabetes, and sexual health. Our Qnexa™ is a proprietary therapeutic formulation & dosing regimen that incorporates the active ingredients from phentermine and topiramate that demonstrate weight loss properties. It simultaneously addresses appetite and satiety, the two main mechanisms that impact eating behavior. Our Avanafil is a specific, highly-selective phosphodiesterase type 5 (PDE5) inhibitor, oral medication under investigation for the treatment of erectile dysfunction (ED).

The company was founded in 1991, has revenues of USD 25-50 Million, has ~40 employees and is ISO 9001 certified. NASDAQ:VVUS (SEC Filings)